CHIZF vs MSFT: Which Stock is Better?
Side-by-side comparison of China Traditional Chinese Medicine Holdings Co. Limited and Microsoft Corp in 2026
CHIZF
China Traditional Chinese Medicine Holdings Co. Limited
$0.27
MSFT
Microsoft Corp
$417.51
Key Metrics Comparison
| Metric | CHIZF | MSFT | Winner |
|---|---|---|---|
| Market Cap | $1.38B | N/A | CHIZF |
| P/E Ratio | N/A | 26.46 | MSFT |
| EPS (TTM) | $N/A | $15.98 | MSFT |
| Revenue Growth | -0.1% | 0.2% | MSFT |
| Gross Margin | 48.1% | 68.6% | MSFT |
Analyze CHIZF
Full quant analysis
Analyze MSFT
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is CHIZF or MSFT a better investment?
Comparing CHIZF and MSFT: China Traditional Chinese Medicine Holdings Co. Limited has a market cap of $1.38B while Microsoft Corp has N/A. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between CHIZF and MSFT?
CHIZF (China Traditional Chinese Medicine Holdings Co. Limited) and MSFT (Microsoft Corp) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: CHIZF or MSFT?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: CHIZF or MSFT?
MSFT has higher revenue growth at 0.2% vs -0.1% for CHIZF.
Which company is more profitable: CHIZF or MSFT?
Microsoft Corp (MSFT) has higher gross margins at 68.6% compared to 48.1% for CHIZF.
Which is the larger company: CHIZF or MSFT?
China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) is larger with a market cap of $1.38B compared to N/A for MSFT.
Should I buy CHIZF or MSFT in 2026?
Both CHIZF and MSFT have investment merit. CHIZF trades at $0.27 while MSFT trades at $417.51. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between CHIZF and MSFT stock?
Key differences: Market Cap ($1.38B vs N/A), P/E Ratio (N/A vs 26.5x), Revenue Growth (-0.1% vs 0.2%), Gross Margin (48.1% vs 68.6%).